Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

doi:10.1200/JCO.2013.50.2047

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Feb 2014

Janin Maxime, Mylonas Elena, Saada Véronique, Micol Jean-Baptiste, Renneville Aline, Quivoron Cyril, Koscielny Serge, Scourzic Laurianne, Forget Sébastien, Pautas Cécile, Caillot Denis, Preudhomme Claude, Dombret Hervé, Berthon Céline, Barouki Robert, Rabier Daniel, Auger Nathalie, Griscelli Frank, Chachaty Elisabeth, Leclercq Edwige, Courtier Marie-Hélène, Bennaceur-Griscelli Annelise, Solary Eric, Bernard Olivier Adrien, Penard-Lacronique Virginie, Ottolenghi Chris, de Botton Stéphane

Abstract excerpt

PURPOSE: Mutated isocitrate dehydrogenases (IDHs) 1 and 2 produce high levels of 2-hydroxyglutarate (2-HG). We investigated whether, in acute myeloid leukemia (AML), serum 2-HG would predict the presence of IDH1/2 mutations at diagnosis and provide a marker of minimal residual disease (MRD). PATIENTS AND METHODS: Serum samples from 82 patients at diagnosis of de novo AML (IDH1/2 mutated, n = 53) and 68 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutarates

Share to Isocitrate Dehydrogenase

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to ROC Curve

Share to Stereoisomerism

Share to WT1 Proteins

Source

Open in PubMed

Identifiers

PMID: 24344214
DOI: 10.1200/JCO.2013.50.2047

Genes

IDH1
IDH2
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.PMID 24344214Read ↗

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Semantic proximity Read ↗

Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.Semantic proximity Read ↗

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.Semantic proximity Read ↗

The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System NeoplasmsSemantic proximity Read ↗

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.Semantic proximity Read ↗

The role of IDH mutations in acute myeloid leukemia.Semantic proximity Read ↗

Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending QuestionsSemantic proximity Read ↗

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.